

ADMET and Solubility Analysis of New 5-Nitroisatine-Based Inhibitors of CDK2 Enzymes

Przemysław Czeleń ^{1,*}, Tomasz Jeliński ¹, Agnieszka Skotnicka ², Beata Szeffler ¹ and Kamil Szupryczyński ³

¹ Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus

University, Kurpińskiego 5, 85-096 Bydgoszcz, Poland; tomasz.jelinski@cm.umk.pl (T.J.); beatas@cm.umk.pl (B.S.)

² Faculty of Chemical Technology and Engineering, Bydgoszcz University of Science and Technology,

Seminaryjna 3, 85-326 Bydgoszcz, Poland; askot@pbs.edu.pl

³ Doctoral School of Medical and Health Sciences, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Kurpińskiego 5, 85-096 Bydgoszcz, Poland; kamilekszapryk@gmail.com

* Correspondence: przemekcz@cm.umk.pl

Supplementary materials




Figure s1. The ¹H NMR spectrum (400 MHz) of 2-trifluoromethyl-*N'*-[5-nitro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]benzohydrazide (1) in DMSO-d₆.




Figure s2. The ^1H NMR spectrum (400 MHz) of 3-Amino-*N'*-[5-nitro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]benzohydrazide (2) in DMSO-d_6 .




Figure s3. The ^1H NMR spectrum (400 MHz) of 3-nitro-*N'*-[5-nitro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene]benzohydrazide (3) in DMSO-d_6 .